Juvenile idiopathic arthritis (JIA) is a heterogeneous group of idiopathic inflammatory arthritis affecting children younger than 16 years of age and lasting six weeks or longer. The terminology of chronic arthritis in children has evolved from juvenile chronic arthritis (JCA) and juvenile rheumatoid arthritis (JRA) to JIA since 1995. The major criteria for the disease include disease beginning before the age of 16 and arthritis in at least one joint that lasts for more than 6 weeks after any other plausible source of joint inflammation has been ruled out. Chronic inflammation of the joints severely restricts the patient's functional abilities and productivity in daily life. The fundamental cause of the aforementioned issues is uncontrolled inflammation. In addition to joint issues, untreated patients may suffer growth retardation, uveitis, blindness, and life-threatening MAS. Adverse pharmacological effects should also be considered (for example, osteoporosis, growth retardation caused by glucocorticoids, and so forth).Thus, JIA treatment should be quick and successful.